Neurocrine Biosciences, Inc. – LSE:0K6R.L
Neurocrine Biosciences stock price today
Neurocrine Biosciences stock price monthly change
Neurocrine Biosciences stock price quarterly change
Neurocrine Biosciences stock price yearly change
Neurocrine Biosciences key metrics
Market Cap | 13.71B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 3.76 |
Revenue | 1.98B |
EBITDA | 482.3M |
Income | 369.7M |
Revenue Q/Q | 22.57% |
Revenue Y/Y | 23.99% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 24.33% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNeurocrine Biosciences stock price history
Neurocrine Biosciences stock forecast
Neurocrine Biosciences financial statements
| Jun 2023 | 452.7M | 95.5M | 21.1% |
|---|---|---|---|
| Sep 2023 | 498.8M | 83.1M | 16.66% |
| Dec 2023 | 515.2M | 147.7M | 28.67% |
| Mar 2024 | 515.29M | 43.4M | 8.42% |
| Dec 2023 | 515.2M | 147.7M | 28.67% |
|---|---|---|---|
| Mar 2024 | 515.29M | 43.4M | 8.42% |
| Sep 2025 | 648.43M | 176.07M | 27.15% |
| Dec 2025 | 678.10M | 184.31M | 27.18% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2613100000 | 760.1M | 29.09% |
|---|---|---|---|
| Sep 2023 | 2848200000 | 846.1M | 29.71% |
| Dec 2023 | 3251400000 | 1.01B | 31.35% |
| Mar 2024 | 3472400000 | 1.08B | 31.28% |
| Jun 2023 | 179.6M | -125.9M | 2.9M |
|---|---|---|---|
| Sep 2023 | 212M | -97.3M | 18.8M |
| Dec 2023 | 123.5M | -201.8M | 35.4M |
| Mar 2024 | 130.3M | -55M | 69.9M |
Neurocrine Biosciences alternative data
| Aug 2023 | 1,300 |
|---|---|
| Sep 2023 | 1,350 |
| Oct 2023 | 1,350 |
| Nov 2023 | 1,350 |
| Dec 2023 | 1,400 |
| Jan 2024 | 1,400 |
| Feb 2024 | 1,400 |
| Mar 2024 | 1,400 |
| Apr 2024 | 1,400 |
| May 2024 | 1,400 |
| Jun 2024 | 1,448 |
| Jul 2024 | 1,448 |
Neurocrine Biosciences other data
| Patent |
|---|
Grant Filling date: 4 Aug 2021 Issue date: 26 Apr 2022 |
Grant Filling date: 19 Oct 2020 Issue date: 26 Apr 2022 |
Application Filling date: 21 Oct 2021 Issue date: 10 Feb 2022 |
Application CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS THEREOF FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA Filling date: 6 Dec 2019 Issue date: 27 Jan 2022 |
Application Filling date: 4 Aug 2021 Issue date: 25 Nov 2021 |
Application N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES Filling date: 26 Apr 2021 Issue date: 4 Nov 2021 |
Application Filling date: 4 Oct 2019 Issue date: 4 Nov 2021 |
Application Filling date: 18 Dec 2020 Issue date: 16 Sep 2021 |
Application Filling date: 1 Apr 2021 Issue date: 22 Jul 2021 |
Grant Utility: [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]is- oquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Filling date: 22 Jan 2020 Issue date: 6 Jul 2021 |
| Insider | Compensation |
|---|---|
Dr. Kevin C. Gorman (1958) Chief Executive Officer & Director | $1,450,000 |
Ms. Eiry Wyn Roberts (1964) Chief Medical Officer | $899,550 |
Mr. Matthew C. Abernethy (1980) Chief Financial Officer | $822,740 |
| Mr. Eric S. Benevich (1965) Chief Commercial Officer | $793,070 |
| Dr. Haig P. Bozigian (1958) Chief Devel. Officer | $780,630 |
| Dr. Dimitri E. Grigoriadis Chief Research Officer | |
Mr. Kyle W. Gano Chief Bus. Devel. and Strategy Officer | |
Ms. Julie Cooke Chief HR Officer | |
Mr. Darin M. Lippoldt Chief Legal Officer & Corporation Sec. | |
Jane Sorensen Head of Investor Relations |
-
What's the price of Neurocrine Biosciences stock today?
One share of Neurocrine Biosciences stock can currently be purchased for approximately $87.28.
-
When is Neurocrine Biosciences's next earnings date?
Unfortunately, Neurocrine Biosciences's (0K6R.L) next earnings date is currently unknown.
-
Does Neurocrine Biosciences pay dividends?
No, Neurocrine Biosciences does not pay dividends.
-
How much money does Neurocrine Biosciences make?
Neurocrine Biosciences has a market capitalization of 13.71B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 26.76% to 1.89B US dollars.
-
What is Neurocrine Biosciences's stock symbol?
Neurocrine Biosciences, Inc. is traded on the LSE under the ticker symbol "0K6R.L".
-
What is Neurocrine Biosciences's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Neurocrine Biosciences?
Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Neurocrine Biosciences's key executives?
Neurocrine Biosciences's management team includes the following people:
- Dr. Kevin C. Gorman Chief Executive Officer & Director(age: 67, pay: $1,450,000)
- Ms. Eiry Wyn Roberts Chief Medical Officer(age: 61, pay: $899,550)
- Mr. Matthew C. Abernethy Chief Financial Officer(age: 45, pay: $822,740)
- Mr. Eric S. Benevich Chief Commercial Officer(age: 60, pay: $793,070)
- Dr. Haig P. Bozigian Chief Devel. Officer(age: 67, pay: $780,630)
- Dr. Dimitri E. Grigoriadis Chief Research Officer
- Mr. Kyle W. Gano Chief Bus. Devel. and Strategy Officer
- Ms. Julie Cooke Chief HR Officer
- Mr. Darin M. Lippoldt Chief Legal Officer & Corporation Sec.
- Jane Sorensen Head of Investor Relations
-
How many employees does Neurocrine Biosciences have?
As Jul 2024, Neurocrine Biosciences employs 1,448 workers, which is 3% more then previous quarter.
-
When Neurocrine Biosciences went public?
Neurocrine Biosciences, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Neurocrine Biosciences's official website?
The official website for Neurocrine Biosciences is neurocrine.com.
-
Where are Neurocrine Biosciences's headquarters?
Neurocrine Biosciences is headquartered at 12780 El Camino Real, San Diego, CA.
-
How can i contact Neurocrine Biosciences?
Neurocrine Biosciences's mailing address is 12780 El Camino Real, San Diego, CA and company can be reached via phone at 858 617 7600.
Neurocrine Biosciences company profile:
Neurocrine Biosciences, Inc.
neurocrine.comLSE
1,700
Medical - Pharmaceuticals
Healthcare
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
San Diego, CA 92130
:
ISIN: US64125C1099
:
